You are here:
  1. PHAIDRA
  2. Detail o:2951
Open in new window
Title (en)
JAK-Inhibitors - A Story of Success and Adverse Events
Language
English
Description (en)
Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Keywords (en)
Protein-Tyrosine Kinase; Rheumatoid-Arthritis; Interferon-Alpha/Beta; Cardiovascular Events; Psoriatic-Arthritis; Cancer-Risk; Tofacitinib; Metaanalysis; Mortality; Inflammation
DOI
10.2147/OARRR.S436637
Author of the digital object
Rebekka Wlassits  (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie)
Mathias Müller  (University of Veterinary Medicine Vienna)
Karl H. Fenzl  (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie)
Thomas Lamprecht  (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie)
Ludwig Erlacher  (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie)
Format
application/pdf
Size
430.5 kB
Licence Selected
CC BY-NC 4.0 International
Type of publication
Article
Name of Publication (de)
Open Access Rheumatology - Research and Reviews
Pages or Volume
11
Volume
16
From Page
43
To Page
53
Publisher
Dove Medical Press Ltd
Publication Date
2024